# A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation

> **NCT00655161** · PHASE2 · COMPLETED · sponsor: **GlobeImmune** · enrollment: 24 (actual)

## Conditions studied

- NSCLC

## Interventions

- **BIOLOGICAL:** GI-4000

## Key facts

- **NCT ID:** NCT00655161
- **Lead sponsor:** GlobeImmune
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00655161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00655161, "A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00655161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*